GB2433592A - Assay for thrombin inhibitors - Google Patents
Assay for thrombin inhibitors Download PDFInfo
- Publication number
- GB2433592A GB2433592A GB0526645A GB0526645A GB2433592A GB 2433592 A GB2433592 A GB 2433592A GB 0526645 A GB0526645 A GB 0526645A GB 0526645 A GB0526645 A GB 0526645A GB 2433592 A GB2433592 A GB 2433592A
- Authority
- GB
- United Kingdom
- Prior art keywords
- thrombin
- sample
- prothrombin
- indirect
- heparin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003868 thrombin inhibitor Substances 0.000 title claims description 11
- 229940122388 Thrombin inhibitor Drugs 0.000 title claims description 6
- 238000003556 assay Methods 0.000 title description 16
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 113
- 229920000669 heparin Polymers 0.000 claims abstract description 107
- 229960002897 heparin Drugs 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 80
- 108090000190 Thrombin Proteins 0.000 claims abstract description 72
- 229960004072 thrombin Drugs 0.000 claims abstract description 72
- 108010094028 Prothrombin Proteins 0.000 claims abstract description 69
- 102100027378 Prothrombin Human genes 0.000 claims abstract description 69
- 229940039716 prothrombin Drugs 0.000 claims abstract description 69
- 229940118340 Indirect thrombin inhibitor Drugs 0.000 claims abstract description 66
- 101001038021 Lonomia obliqua Lopap Proteins 0.000 claims abstract description 57
- 230000000694 effects Effects 0.000 claims abstract description 52
- 230000035602 clotting Effects 0.000 claims abstract description 43
- 206010053567 Coagulopathies Diseases 0.000 claims abstract description 41
- 239000003998 snake venom Substances 0.000 claims abstract description 19
- 239000000758 substrate Substances 0.000 claims abstract description 9
- 230000008859 change Effects 0.000 claims abstract description 7
- 108010074860 Factor Xa Proteins 0.000 claims abstract description 5
- 108090001115 snake venom factor V activator Proteins 0.000 claims abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 60
- 230000015271 coagulation Effects 0.000 claims description 34
- 238000005345 coagulation Methods 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 32
- 230000004913 activation Effects 0.000 claims description 19
- 102000007327 Protamines Human genes 0.000 claims description 15
- 108010007568 Protamines Proteins 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 14
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 14
- 239000003114 blood coagulation factor Substances 0.000 claims description 14
- 238000011002 quantification Methods 0.000 claims description 14
- 229940048914 protamine Drugs 0.000 claims description 12
- 239000005557 antagonist Substances 0.000 claims description 11
- 239000004019 antithrombin Substances 0.000 claims description 10
- 239000012503 blood component Substances 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 108010054218 Factor VIII Proteins 0.000 claims description 7
- 102000001690 Factor VIII Human genes 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000002628 heparin derivative Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 229960000301 factor viii Drugs 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 5
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 4
- 108010023321 Factor VII Proteins 0.000 claims description 4
- 108010049003 Fibrinogen Proteins 0.000 claims description 4
- 102000008946 Fibrinogen Human genes 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 229940012413 factor vii Drugs 0.000 claims description 4
- 229940012952 fibrinogen Drugs 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 108010033967 trocarin Proteins 0.000 claims description 4
- 108010039627 Aprotinin Proteins 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 229920001499 Heparinoid Polymers 0.000 claims description 3
- 229960004405 aprotinin Drugs 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims description 3
- 229960001318 fondaparinux Drugs 0.000 claims description 3
- 239000002554 heparinoid Substances 0.000 claims description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 3
- 239000003055 low molecular weight heparin Substances 0.000 claims description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 2
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 2
- 108010076282 Factor IX Proteins 0.000 claims description 2
- 108010014172 Factor V Proteins 0.000 claims description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 2
- 229940051593 dermatan sulfate Drugs 0.000 claims description 2
- 229960004222 factor ix Drugs 0.000 claims description 2
- 108010074864 Factor XI Proteins 0.000 claims 1
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 claims 1
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 claims 1
- 229940122920 Kallikrein inhibitor Drugs 0.000 claims 1
- 102100023012 Kallistatin Human genes 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 42
- 210000004369 blood Anatomy 0.000 abstract description 42
- 239000003112 inhibitor Substances 0.000 abstract description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract description 2
- 239000001110 calcium chloride Substances 0.000 abstract description 2
- 229910001628 calcium chloride Inorganic materials 0.000 abstract description 2
- 239000002821 viper venom Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 82
- 239000012190 activator Substances 0.000 description 27
- 239000003146 anticoagulant agent Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 20
- 238000001514 detection method Methods 0.000 description 15
- 208000007536 Thrombosis Diseases 0.000 description 14
- 231100000673 dose–response relationship Toxicity 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 238000001356 surgical procedure Methods 0.000 description 12
- 229940127219 anticoagulant drug Drugs 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000000630 rising effect Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- -1 e.g. Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000010100 anticoagulation Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000006623 intrinsic pathway Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 4
- 102000002262 Thromboplastin Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229920001221 xylan Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000006624 extrinsic pathway Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229940025770 heparinoids Drugs 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000013169 thromboelastometry Methods 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 241000271032 Daboia russelii Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 101710144447 Factor V activator Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108090000481 Heparin Cofactor II Proteins 0.000 description 1
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 1
- 101000918470 Homo sapiens Coagulation factor X Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940127379 Kallikrein Inhibitors Drugs 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 101710181904 Venom factor Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229940107792 certoparin Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960004969 dalteparin Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 108010085662 ecarin Proteins 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940087051 fragmin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229940099813 human coagulation factor x Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940095443 innohep Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108010011227 meizothrombin Proteins 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000005486 microgravity Effects 0.000 description 1
- 229960000899 nadroparin Drugs 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 108010065506 platelet factor V Proteins 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960005496 reviparin Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229920002351 sodium apolate Polymers 0.000 description 1
- 229960003968 sodium apolate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- BWYYYTVSBPRQCN-UHFFFAOYSA-M sodium;ethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=C BWYYYTVSBPRQCN-UHFFFAOYSA-M 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- SYRHIZPPCHMRIT-UHFFFAOYSA-N tin(4+) Chemical compound [Sn+4] SYRHIZPPCHMRIT-UHFFFAOYSA-N 0.000 description 1
- 229960005062 tinzaparin Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4905—Determining clotting time of blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96463—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Ecology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0526645A GB2433592A (en) | 2005-12-23 | 2005-12-23 | Assay for thrombin inhibitors |
| PCT/IB2006/003734 WO2007072197A1 (en) | 2005-12-23 | 2006-12-21 | Methods and systems for detecting and quantifying indirect thrombin inhibitors |
| DE112006003476T DE112006003476T5 (de) | 2005-12-23 | 2006-12-21 | Verfahren und Systeme zum Nachweisen und Quantifizieren indirekter Thrombininhibitoren |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0526645A GB2433592A (en) | 2005-12-23 | 2005-12-23 | Assay for thrombin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0526645D0 GB0526645D0 (en) | 2006-02-08 |
| GB2433592A true GB2433592A (en) | 2007-06-27 |
Family
ID=35841407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0526645A Withdrawn GB2433592A (en) | 2005-12-23 | 2005-12-23 | Assay for thrombin inhibitors |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE112006003476T5 (de) |
| GB (1) | GB2433592A (de) |
| WO (1) | WO2007072197A1 (de) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2492104A (en) * | 2011-06-22 | 2012-12-26 | Job Harenberg | Assay for direct thrombin inhibitors |
| WO2016061611A1 (en) | 2014-10-23 | 2016-04-28 | Q-Sera Pty Ltd | Improved clotting composition |
| CN108982865A (zh) * | 2018-08-16 | 2018-12-11 | 上海原科实业发展有限公司 | 一种血栓弹力图法肝素定量检测试剂盒及其制备方法 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6133777B2 (ja) * | 2010-09-20 | 2017-05-24 | キュー−セラ プロプライエタリー リミテッド | 血清の調製 |
| CN104459165B (zh) * | 2014-12-10 | 2016-07-06 | 中国医学科学院输血研究所 | 一种检测人凝血酶原复合物抗凝能力的方法 |
| CN107746804A (zh) * | 2017-11-28 | 2018-03-02 | 世纪亿康（天津）医疗科技发展有限公司 | 针对添加肝素血液样本的凝血及血小板功能检测试剂盒及其应用 |
| CN110514851A (zh) * | 2019-08-28 | 2019-11-29 | 深圳麦科田生物医疗技术有限公司 | 血小板抑制率的检测方法和检测试剂盒 |
| CN111549005B (zh) * | 2020-05-14 | 2021-05-11 | 山东省科学院生物研究所 | 一种凝血酶原激活因子及含凝血酶原激活因子的快速止血材料 |
| CN115032164B (zh) * | 2022-08-10 | 2022-12-06 | 山东省食品药品检验研究院 | 一种肝素钠中是否含有凝血因子Xa直接抑制剂的检测方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946775A (en) * | 1985-09-05 | 1990-08-07 | Yin E Thye | Composition, kit and method for assaying heparin and a method for making the composition |
| US5547850A (en) * | 1992-02-11 | 1996-08-20 | Max-Planck-Gesellschaft | Process for determining hirudin and synthetic thrombin inhibitors |
| US6140062A (en) * | 1997-06-27 | 2000-10-31 | Universiteit Maastricht | Method of determining the heparin content |
| US20020019021A1 (en) * | 1997-11-07 | 2002-02-14 | Michael Kraus | Method for determining the anticoagulatory potential of a sample |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3492096A (en) | 1967-10-05 | 1970-01-27 | Paul G Hattersley | Apparatus for and method of detecting the coagulation of whole blood |
| US4756884A (en) | 1985-08-05 | 1988-07-12 | Biotrack, Inc. | Capillary flow device |
| US5110727A (en) | 1987-04-03 | 1992-05-05 | Cardiovascular Diagnostics, Inc. | Method for performing coagulation assays accurately, rapidly and simply, using dry chemical reagents and paramagnetic particles |
| WO1996012954A1 (de) | 1994-10-19 | 1996-05-02 | Alexander Calatzis | Vorrichtung zum messen der koagulationseigenschaften von test-flüssigkeiten |
| AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| US6046051A (en) | 1997-06-27 | 2000-04-04 | Hemosense, Inc. | Method and device for measuring blood coagulation or lysis by viscosity changes |
| US6272176B1 (en) | 1998-07-16 | 2001-08-07 | Nielsen Media Research, Inc. | Broadcast encoding system and method |
| US6417004B1 (en) | 1999-04-29 | 2002-07-09 | Helena Laboratories Corporation | Enhancing clot detection in activated clotting time and other fibrin endpoint based tests |
| WO2001044493A2 (en) * | 1999-12-15 | 2001-06-21 | Pentapharm Ag | Hematological assay and reagent |
| AU2001291549A1 (en) | 2000-09-08 | 2002-03-22 | Hamilton Civic Hospitals Research Development Inc. | Antithrombotic compositions |
| US20020069143A1 (en) | 2000-12-06 | 2002-06-06 | Cepeda Jose Alberto | System and method for allocating operating expenses |
| EP1367135A1 (de) * | 2002-05-29 | 2003-12-03 | Pentapharm AG | Verbessertes Verfahren zur Beurteilung der Thrombinbildung in Blutplasma |
| ES2390271T3 (es) * | 2003-09-22 | 2012-11-08 | University Of North Carolina At Chapel Hill | Fosfolípidos solubles para uso en ensayos de factores de coagulación |
-
2005
- 2005-12-23 GB GB0526645A patent/GB2433592A/en not_active Withdrawn
-
2006
- 2006-12-21 WO PCT/IB2006/003734 patent/WO2007072197A1/en active Application Filing
- 2006-12-21 DE DE112006003476T patent/DE112006003476T5/de not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946775A (en) * | 1985-09-05 | 1990-08-07 | Yin E Thye | Composition, kit and method for assaying heparin and a method for making the composition |
| US5547850A (en) * | 1992-02-11 | 1996-08-20 | Max-Planck-Gesellschaft | Process for determining hirudin and synthetic thrombin inhibitors |
| US6140062A (en) * | 1997-06-27 | 2000-10-31 | Universiteit Maastricht | Method of determining the heparin content |
| US20020019021A1 (en) * | 1997-11-07 | 2002-02-14 | Michael Kraus | Method for determining the anticoagulatory potential of a sample |
Non-Patent Citations (3)
| Title |
|---|
| American Journal of Clinical Pathology (2004); Vol 122, pp 836-842, "Improved distinction of Factor V...", Wilmer et al * |
| BIOSIS Accession No PREV200100307066 & Blood (2000); Vol 96, pp 94b-p5b, "Chronometric analysis of heparins on...", Gempeler-Messina et al * |
| Thrombosis Research (1996); Vol 83, pp 363-373, "APC-resistance as measured by a...", Hoagland et al * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2492104A (en) * | 2011-06-22 | 2012-12-26 | Job Harenberg | Assay for direct thrombin inhibitors |
| WO2016061611A1 (en) | 2014-10-23 | 2016-04-28 | Q-Sera Pty Ltd | Improved clotting composition |
| JP2017532581A (ja) * | 2014-10-23 | 2017-11-02 | キュー−セラ ピーティーワイ リミテッド | 改善された凝固組成物 |
| US10786553B2 (en) | 2014-10-23 | 2020-09-29 | Q-Sera Pty Ltd. | Clotting composition |
| JP2020173258A (ja) * | 2014-10-23 | 2020-10-22 | キュー−セラ ピーティーワイ リミテッド | 改善された凝固組成物 |
| AU2015336925B2 (en) * | 2014-10-23 | 2020-11-26 | Q-Sera Pty Ltd | Improved clotting composition |
| US11103560B2 (en) | 2014-10-23 | 2021-08-31 | Q-Sera Pty Ltd. | Clotting composition |
| CN108982865A (zh) * | 2018-08-16 | 2018-12-11 | 上海原科实业发展有限公司 | 一种血栓弹力图法肝素定量检测试剂盒及其制备方法 |
| CN108982865B (zh) * | 2018-08-16 | 2021-05-11 | 上海原科实业发展有限公司 | 一种血栓弹力图法肝素定量检测试剂盒及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0526645D0 (en) | 2006-02-08 |
| WO2007072197A1 (en) | 2007-06-28 |
| DE112006003476T5 (de) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2433592A (en) | Assay for thrombin inhibitors | |
| AU757459B2 (en) | Inhibition of coagulation in blood and blood products | |
| EP0420332B1 (de) | Verfahren zur Bestimmung des endogenen Thrombinpotentials von Plasma und Blut und Reagenziensatz zur Verwendung in besagtem Verfahren | |
| Kitchen | Problems in laboratory monitoring of heparin dosage. | |
| CN108982865B (zh) | 一种血栓弹力图法肝素定量检测试剂盒及其制备方法 | |
| CA2252983C (en) | Method for determining the anticoagulatory potential of a sample | |
| CA2392350C (en) | Hematological assay and reagent | |
| WO2002079375A1 (en) | Rapid assessment of coagulation activity in whole blood | |
| EP0830608B1 (de) | Test für thrombosegefahr | |
| JP5118321B2 (ja) | ヘパリン修飾成分を用いた第Ｘａ因子に基づくヘパリンアッセイ | |
| Calatzis et al. | Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors | |
| Walenga et al. | Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions | |
| WO2000013027A1 (en) | Diagnosis of atherosclerosis by 'face' measurement of heparin | |
| US7727736B2 (en) | Soluble phospholipids for use in clotting factor assays | |
| HU219457B (hu) | Meizotrombint, meizotrombin(des F1)-t vagy keverékeiket tartalmazó reagens, valamint tesztkészlet diagnosztikai célokra | |
| Ozawa et al. | Determination of Low–Molecular-Weight Heparin by Heptest on the Automated Coagulation Laboratory System | |
| US20240060999A1 (en) | Blood coagulation inspection method | |
| Thachil | The abnormal clotting profile | |
| Koroleva et al. | Standardization of the protein calibrators isolation methodology for thrombophilia markers detecting immunodiagnostic test systems | |
| Demir et al. | Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques | |
| MXPA97009961A (en) | Trombo risk test |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |